BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 52.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 529,419 shares of the biotechnology company's stock after selling 580,485 shares during the quarter. Assenagon Asset Management S.A. owned 0.26% of BioCryst Pharmaceuticals worth $3,171,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Braidwell LP lifted its holdings in BioCryst Pharmaceuticals by 92.1% during the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company's stock worth $37,970,000 after buying an additional 2,571,100 shares in the last quarter. Jump Financial LLC raised its stake in shares of BioCryst Pharmaceuticals by 371.5% in the third quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company's stock valued at $2,867,000 after acquiring an additional 319,037 shares in the last quarter. Kynam Capital Management LP raised its stake in shares of BioCryst Pharmaceuticals by 184.8% in the second quarter. Kynam Capital Management LP now owns 2,848,197 shares of the biotechnology company's stock valued at $20,051,000 after acquiring an additional 1,848,197 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its holdings in BioCryst Pharmaceuticals by 148.6% in the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company's stock valued at $23,265,000 after purchasing an additional 1,964,000 shares during the period. Finally, Rice Hall James & Associates LLC grew its stake in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company's stock worth $16,112,000 after purchasing an additional 402,674 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, January 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $13.29.

BioCryst Pharmaceuticals Trading Up 0.9 %

NASDAQ:BCRX traded up $0.04 during trading hours on Wednesday, hitting $4.73. The company's stock had a trading volume of 3,058,481 shares, compared to its average volume of 3,375,412. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.59 and a 52-week high of $9.06. The stock has a market capitalization of $975.09 million, a P/E ratio of -4.01 and a beta of 1.90. The stock has a fifty day moving average of $5.38 and a 200-day moving average of $5.81.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $89.19 million. On average, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.62 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.